このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

米国南東部の住民が高血圧を止めるための食料品 (GoFreshSE)

2026年11月14日 更新者:Stephen Juraschek、Beth Israel Deaconess Medical Center

GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.

調査の概要

詳細な説明

Hypertension (HTN) affects half of US adults and is one of the most important modifiable risk factors for cardiovascular disease (CVD) and death.

The DASH diet is a proven strategy for lowering blood pressure in adults. Our proposed clinical trial will evaluate the effectiveness of a scalable solution: home-delivered, low-sodium groceries aligned with the DASH dietary pattern and ordered with dietitian assistance via a virtual supermarket, in reducing blood pressure.

Participants will be assigned to one of two 1-month long interventions: (1) dietitian-assisted, DASH-patterned, home-delivered groceries ordered weekly through Amazon Fresh (or Whole Foods) over 4 weeks or (2) self-directed grocery shopping (monthly stipend and DASH diet brochure) (referent).

研究の種類

介入

入学 (推定)

150

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Beth Israel Deaconess Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Resting systolic blood pressure of 120 to <160 mm Hg and diastolic blood pressure <110 mm Hg
  2. Resident of Florida, Georgia, and Tennessee
  3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period
  4. Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service
  5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send/receive text messages
  6. Willing and able to complete required measurement procedures
  7. Able to provide consent for the study
  8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study

Exclusion Criteria:

A. Laboratory Exclusions:

  1. Serum potassium ≥5.4 mmol/L or <3.5 mmol/L
  2. Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  3. Hemoglobin A1c ≥6.5%

B. Medication Exclusions:

Unstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following:

  1. GLP-1 and dual GLP-1/GIP receptor agonists
  2. Anti-hypertension medications
  3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  4. Glucose lowering medications

Use of any of the following medications:

  1. Potassium supplement, except if part of a multivitamin
  2. Warfarin (Coumadin)
  3. Chronic oral corticosteroid (intermittent use is okay)
  4. Weight loss medications (non-GLP-1 receptor agonists)
  5. Sulfonylurea or any insulin use

Any medication not compatible with participation as determined by the investigators

C. Physical Exclusions:

  1. Systolic blood pressure: <120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg
  2. Arm circumference >52 cm (or the upper limit of the validated BP device)

D. Medical History Exclusions:

  1. Self-reported weight loss or gain of 15 pounds during prior 2 months
  2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission
  3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)
  4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence
  5. Pregnancy or lactation or planned pregnancy during the study period
  6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months
  7. Hypoglycemia hospitalization in the last 12 months
  8. Any other serious illness or condition not compatible with participation as determined by the investigators

E. Lifestyle and Other Exclusions:

  1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence
  2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week
  3. Active substance use disorder that would interfere with participation
  4. Extreme food insecurity
  5. Participation in or planning to start weight loss program
  6. Current participation in another clinical trial that could interfere with the study protocol
  7. Anticipated change in residence outside of eligible states prior to the end of the study
  8. Families with more than 6 adults at dinner time (children count as half an adult)

F. Investigator discretion

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dietitian-Assisted DASH Groceries

Participants will order groceries sufficient to meet their caloric needs each week for 4 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions.

The DASH ("Dietary Approaches to Stop Hypertension"), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.

Intervention Phase:

This intervention is a weekly, 4-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.

アクティブコンパレータ:Self-directed shopping

Participants will receive a stipend and some basic information about healthy eating. The stipend is not restricted to foods.

Intervention Phase:

Participants will receive some basic information on healthy eating and a stipend during the 4-week intervention period. They are permitted to use the stipend however they choose and will not be asked about how they spent these funds.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Self-measured systolic blood pressure
時間枠:Measured before and after the 4-week intervention

This entails 4 measurements, 2 in the morning and 2 in the evening, over a 7 day period (at least 3 concurrent days is acceptable for analysis).

Measured before and after the 4-week intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Self-measured diastolic blood pressure
時間枠:Measured before and after the 4-week intervention

This entails 4 measurements, 2 in the morning and 2 in the evening, over a 7 day period (at least 3 concurrent days is acceptable for analysis).

Measured before and after the 4-week intervention
Seated systolic and diastolic blood pressure (technician-measured)
時間枠:Measured before and after the 4-week intervention

Seated systolic and diastolic blood pressure measured by a technician in participants' homes, using the office blood pressure device.

Measured before and after the 4-week intervention
Body Mass Index (BMI)
時間枠:Height is measured before the intervention. Weight is measured before and after the 4-week intervention.

At home measurement based on height and weight measured by a technician via a stadiometer and scale.

Height is measured before the intervention. Weight is measured before and after the 4-week intervention.
24-hour dietary recall
時間枠:Measured before and after the 4-week intervention

Assessed via self-administered questionnaire using the Automated Self-Administered 24-Hour Dietary Recall (ASA24).

Measured before and after the 4-week intervention
Spot urine sodium/potassium ratio
時間枠:Measured before and after the 4-week intervention

Measured in urine collected at the participants' homes.

Measured before and after the 4-week intervention
Lipids
時間枠:Measured before and after the 4-week intervention

Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides

Measured before and after the 4-week intervention
Fasting glucose
時間枠:Measured before and after the 4-week intervention

Measured in blood as part of a basic metabolic panel

Measured before and after the 4-week intervention
Serum potassium
時間枠:Measured before and after the 4-week intervention

Measured in blood as part of a basic metabolic panel

Measured before and after the 4-week intervention

その他の成果指標

結果測定
メジャーの説明
時間枠
General Health Status
時間枠:Measured before and after the 4-week intervention

Single General Health Status Question: "Would you say that in general your health is excellent, very good, good, fair, or poor?"

Measured before and after the 4-week intervention
Financial strain
時間枠:Measured before and after the 4-week intervention

We will ask the following questions: How often does this describe you? I don't have money to pay my bills (including food, housing, medical care or heating).

Never / Rarely / Sometimes / Often / Always

Measured before and after the 4-week intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年10月14日

一次修了 (推定)

2026年11月1日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2025年3月18日

QC基準を満たした最初の提出物

2025年3月18日

最初の投稿 (実際)

2025年3月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月14日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 2025P000102
  • GRT67144 (その他の助成金/資金番号:American Heart Association)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する